Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma
BACKGROUND Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied. METHODS Arginase activity was monitored in serum from 40 patients with pr...
Gespeichert in:
Veröffentlicht in: | Cancer 2002-06, Vol.94 (11), p.2930-2934 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2934 |
---|---|
container_issue | 11 |
container_start_page | 2930 |
container_title | Cancer |
container_volume | 94 |
creator | Porembska, Zofia Skwarek, Anna Mielczarek, Magdalena Barańczyk‐Kuźma, Anna |
description | BACKGROUND
Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied.
METHODS
Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years.
RESULTS
Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut‐off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died.
CONCLUSIONS
The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM. Cancer 2002;94:2930–4. © 2002 American Cancer Society.
DOI 10.1002/cncr.10563
The determination of serum arginase activity may be a complementary test confirming the occurrence of colorectal carcinoma and can be useful for the early diagnosis of patients with recurrent colorectal carcinoma and/or liver metastases. |
doi_str_mv | 10.1002/cncr.10563 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71894986</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71894986</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3553-8d6cbbea162032e08408d3d5236521a9e379bf535ab4b51f7f3617f67a217ecf3</originalsourceid><addsrcrecordid>eNp90E1LwzAYwPEgipvTix9ActGDUM1L07RHKb7BUPAFditplsxIm8wkdezbm7mBN09JyI_ngT8ApxhdYYTItbTSpxsr6B4YY1TxDOGc7IMxQqjMWE5nI3AUwmd6csLoIRhhgjGjJR6D2avyQw-FXxgrgoJCRvNt4hoaC5cuxDCkHyk62DtrovPGLqDTcCmiUTYGuDLxA0rXOa9kTEwKL411vTgGB1p0QZ3szgl4v7t9qx-y6fP9Y30zzSRljGblvJBtqwQuCKJEoTJH5ZzOGaEFI1hUivKq1Ywy0eYtw5prWmCuCy4I5kpqOgEX27lL774GFWLTmyBV1wmr3BAajssqr8oiwcstlN6F4JVult70wq8bjJpNx2bTsfntmPDZburQ9mr-R3fhEjjfARFSHu2FlSb8OVrwnCGeHN66lenU-p-VTf1Uv2yX_wCCqouL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71894986</pqid></control><display><type>article</type><title>Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Porembska, Zofia ; Skwarek, Anna ; Mielczarek, Magdalena ; Barańczyk‐Kuźma, Anna</creator><creatorcontrib>Porembska, Zofia ; Skwarek, Anna ; Mielczarek, Magdalena ; Barańczyk‐Kuźma, Anna</creatorcontrib><description>BACKGROUND
Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied.
METHODS
Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years.
RESULTS
Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut‐off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died.
CONCLUSIONS
The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM. Cancer 2002;94:2930–4. © 2002 American Cancer Society.
DOI 10.1002/cncr.10563
The determination of serum arginase activity may be a complementary test confirming the occurrence of colorectal carcinoma and can be useful for the early diagnosis of patients with recurrent colorectal carcinoma and/or liver metastases.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.10563</identifier><identifier>PMID: 12115381</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma - enzymology ; Adenocarcinoma - secondary ; Adenocarcinoma - surgery ; Adult ; Aged ; arginase ; Arginase - blood ; Biological and medical sciences ; Biomarkers, Tumor - blood ; colorectal liver metastases ; Colorectal Neoplasms - enzymology ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - surgery ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; human colorectal carcinoma ; Humans ; Liver Neoplasms - enzymology ; Liver Neoplasms - secondary ; Liver Neoplasms - surgery ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - enzymology ; Neoplasm Recurrence, Local - secondary ; Neoplasm Recurrence, Local - surgery ; Postoperative Care ; Preoperative Care ; Prognosis ; serum marker ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors</subject><ispartof>Cancer, 2002-06, Vol.94 (11), p.2930-2934</ispartof><rights>Copyright © 2002 American Cancer Society</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2002 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3553-8d6cbbea162032e08408d3d5236521a9e379bf535ab4b51f7f3617f67a217ecf3</citedby><cites>FETCH-LOGICAL-c3553-8d6cbbea162032e08408d3d5236521a9e379bf535ab4b51f7f3617f67a217ecf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.10563$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.10563$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13674507$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12115381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Porembska, Zofia</creatorcontrib><creatorcontrib>Skwarek, Anna</creatorcontrib><creatorcontrib>Mielczarek, Magdalena</creatorcontrib><creatorcontrib>Barańczyk‐Kuźma, Anna</creatorcontrib><title>Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied.
METHODS
Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years.
RESULTS
Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut‐off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died.
CONCLUSIONS
The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM. Cancer 2002;94:2930–4. © 2002 American Cancer Society.
DOI 10.1002/cncr.10563
The determination of serum arginase activity may be a complementary test confirming the occurrence of colorectal carcinoma and can be useful for the early diagnosis of patients with recurrent colorectal carcinoma and/or liver metastases.</description><subject>Adenocarcinoma - enzymology</subject><subject>Adenocarcinoma - secondary</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>arginase</subject><subject>Arginase - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>colorectal liver metastases</subject><subject>Colorectal Neoplasms - enzymology</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>human colorectal carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - enzymology</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - enzymology</subject><subject>Neoplasm Recurrence, Local - secondary</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Postoperative Care</subject><subject>Preoperative Care</subject><subject>Prognosis</subject><subject>serum marker</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90E1LwzAYwPEgipvTix9ActGDUM1L07RHKb7BUPAFditplsxIm8wkdezbm7mBN09JyI_ngT8ApxhdYYTItbTSpxsr6B4YY1TxDOGc7IMxQqjMWE5nI3AUwmd6csLoIRhhgjGjJR6D2avyQw-FXxgrgoJCRvNt4hoaC5cuxDCkHyk62DtrovPGLqDTcCmiUTYGuDLxA0rXOa9kTEwKL411vTgGB1p0QZ3szgl4v7t9qx-y6fP9Y30zzSRljGblvJBtqwQuCKJEoTJH5ZzOGaEFI1hUivKq1Ywy0eYtw5prWmCuCy4I5kpqOgEX27lL774GFWLTmyBV1wmr3BAajssqr8oiwcstlN6F4JVult70wq8bjJpNx2bTsfntmPDZburQ9mr-R3fhEjjfARFSHu2FlSb8OVrwnCGeHN66lenU-p-VTf1Uv2yX_wCCqouL</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>Porembska, Zofia</creator><creator>Skwarek, Anna</creator><creator>Mielczarek, Magdalena</creator><creator>Barańczyk‐Kuźma, Anna</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020601</creationdate><title>Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma</title><author>Porembska, Zofia ; Skwarek, Anna ; Mielczarek, Magdalena ; Barańczyk‐Kuźma, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3553-8d6cbbea162032e08408d3d5236521a9e379bf535ab4b51f7f3617f67a217ecf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adenocarcinoma - enzymology</topic><topic>Adenocarcinoma - secondary</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>arginase</topic><topic>Arginase - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>colorectal liver metastases</topic><topic>Colorectal Neoplasms - enzymology</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>human colorectal carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - enzymology</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - enzymology</topic><topic>Neoplasm Recurrence, Local - secondary</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Postoperative Care</topic><topic>Preoperative Care</topic><topic>Prognosis</topic><topic>serum marker</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Porembska, Zofia</creatorcontrib><creatorcontrib>Skwarek, Anna</creatorcontrib><creatorcontrib>Mielczarek, Magdalena</creatorcontrib><creatorcontrib>Barańczyk‐Kuźma, Anna</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Porembska, Zofia</au><au>Skwarek, Anna</au><au>Mielczarek, Magdalena</au><au>Barańczyk‐Kuźma, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>94</volume><issue>11</issue><spage>2930</spage><epage>2934</epage><pages>2930-2934</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied.
METHODS
Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years.
RESULTS
Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut‐off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died.
CONCLUSIONS
The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM. Cancer 2002;94:2930–4. © 2002 American Cancer Society.
DOI 10.1002/cncr.10563
The determination of serum arginase activity may be a complementary test confirming the occurrence of colorectal carcinoma and can be useful for the early diagnosis of patients with recurrent colorectal carcinoma and/or liver metastases.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>12115381</pmid><doi>10.1002/cncr.10563</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-543X |
ispartof | Cancer, 2002-06, Vol.94 (11), p.2930-2934 |
issn | 0008-543X 1097-0142 |
language | eng |
recordid | cdi_proquest_miscellaneous_71894986 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Adenocarcinoma - enzymology Adenocarcinoma - secondary Adenocarcinoma - surgery Adult Aged arginase Arginase - blood Biological and medical sciences Biomarkers, Tumor - blood colorectal liver metastases Colorectal Neoplasms - enzymology Colorectal Neoplasms - pathology Colorectal Neoplasms - surgery Female Gastroenterology. Liver. Pancreas. Abdomen human colorectal carcinoma Humans Liver Neoplasms - enzymology Liver Neoplasms - secondary Liver Neoplasms - surgery Male Medical sciences Middle Aged Neoplasm Recurrence, Local - enzymology Neoplasm Recurrence, Local - secondary Neoplasm Recurrence, Local - surgery Postoperative Care Preoperative Care Prognosis serum marker Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors |
title | Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T06%3A57%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20arginase%20activity%20in%20postsurgical%20monitoring%20of%20patients%20with%20colorectal%20carcinoma&rft.jtitle=Cancer&rft.au=Porembska,%20Zofia&rft.date=2002-06-01&rft.volume=94&rft.issue=11&rft.spage=2930&rft.epage=2934&rft.pages=2930-2934&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.10563&rft_dat=%3Cproquest_cross%3E71894986%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71894986&rft_id=info:pmid/12115381&rfr_iscdi=true |